Detection of chromosome 13 deletions by fluorescent in situ hybridization.

Scott VanWier, Rafael Fonseca

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Multiple myeloma (MM), like other hematological malignancies, has both normal and clonal neoplastic cells coresiding in the bone marrow. To perform interphase fluorescent in situ hybridization (FISH) analysis accurately, for the detection of clonal chromosome abnormalities, it is crucial to restrict the analysis to the tumoral cells. The correct detection of these abnormalities may have diagnostic, prognostic, and therapeutic implications. Our laboratory has developed a clone-specific cytoplasmic immunoglobulin (cIg) staining method coupled with FISH (cIg-FISH) for the study of plasma cell (PC) neoplasms. An unlimited combination of DNA probes can be used with this technique to examine the genetic changes that frequently occur in patients with these diseases, one of which is abnormalities of chromosome 13. Using the two techniques simultaneously (i.e., cIg-FISH), we have demonstrated that approx 50% of patients with MM have abnormalities of chromosome 13, mostly monosomy, and when present involving the majority of the cells. In this chapter, we present the technical methodology for detecting chromosome abnormalities and how to restrict the analysis to the clonal PCs.

Original languageEnglish (US)
Pages (from-to)59-69
Number of pages11
JournalMethods in molecular medicine
Volume113
StatePublished - 2005

Fingerprint

Chromosomes, Human, Pair 13
Chromosome Deletion
Fluorescence In Situ Hybridization
Immunoglobulins
Multiple Myeloma
Chromosome Aberrations
Plasma Cell Neoplasms
Monosomy
Interphase
DNA Probes
Hematologic Neoplasms
Clone Cells
Bone Marrow
Staining and Labeling
Therapeutics

Cite this

Detection of chromosome 13 deletions by fluorescent in situ hybridization. / VanWier, Scott; Fonseca, Rafael.

In: Methods in molecular medicine, Vol. 113, 2005, p. 59-69.

Research output: Contribution to journalArticle

@article{b525ac4141624d239f6017645289d002,
title = "Detection of chromosome 13 deletions by fluorescent in situ hybridization.",
abstract = "Multiple myeloma (MM), like other hematological malignancies, has both normal and clonal neoplastic cells coresiding in the bone marrow. To perform interphase fluorescent in situ hybridization (FISH) analysis accurately, for the detection of clonal chromosome abnormalities, it is crucial to restrict the analysis to the tumoral cells. The correct detection of these abnormalities may have diagnostic, prognostic, and therapeutic implications. Our laboratory has developed a clone-specific cytoplasmic immunoglobulin (cIg) staining method coupled with FISH (cIg-FISH) for the study of plasma cell (PC) neoplasms. An unlimited combination of DNA probes can be used with this technique to examine the genetic changes that frequently occur in patients with these diseases, one of which is abnormalities of chromosome 13. Using the two techniques simultaneously (i.e., cIg-FISH), we have demonstrated that approx 50{\%} of patients with MM have abnormalities of chromosome 13, mostly monosomy, and when present involving the majority of the cells. In this chapter, we present the technical methodology for detecting chromosome abnormalities and how to restrict the analysis to the clonal PCs.",
author = "Scott VanWier and Rafael Fonseca",
year = "2005",
language = "English (US)",
volume = "113",
pages = "59--69",
journal = "Methods in molecular medicine",
issn = "1543-1894",
publisher = "Humana Press",

}

TY - JOUR

T1 - Detection of chromosome 13 deletions by fluorescent in situ hybridization.

AU - VanWier, Scott

AU - Fonseca, Rafael

PY - 2005

Y1 - 2005

N2 - Multiple myeloma (MM), like other hematological malignancies, has both normal and clonal neoplastic cells coresiding in the bone marrow. To perform interphase fluorescent in situ hybridization (FISH) analysis accurately, for the detection of clonal chromosome abnormalities, it is crucial to restrict the analysis to the tumoral cells. The correct detection of these abnormalities may have diagnostic, prognostic, and therapeutic implications. Our laboratory has developed a clone-specific cytoplasmic immunoglobulin (cIg) staining method coupled with FISH (cIg-FISH) for the study of plasma cell (PC) neoplasms. An unlimited combination of DNA probes can be used with this technique to examine the genetic changes that frequently occur in patients with these diseases, one of which is abnormalities of chromosome 13. Using the two techniques simultaneously (i.e., cIg-FISH), we have demonstrated that approx 50% of patients with MM have abnormalities of chromosome 13, mostly monosomy, and when present involving the majority of the cells. In this chapter, we present the technical methodology for detecting chromosome abnormalities and how to restrict the analysis to the clonal PCs.

AB - Multiple myeloma (MM), like other hematological malignancies, has both normal and clonal neoplastic cells coresiding in the bone marrow. To perform interphase fluorescent in situ hybridization (FISH) analysis accurately, for the detection of clonal chromosome abnormalities, it is crucial to restrict the analysis to the tumoral cells. The correct detection of these abnormalities may have diagnostic, prognostic, and therapeutic implications. Our laboratory has developed a clone-specific cytoplasmic immunoglobulin (cIg) staining method coupled with FISH (cIg-FISH) for the study of plasma cell (PC) neoplasms. An unlimited combination of DNA probes can be used with this technique to examine the genetic changes that frequently occur in patients with these diseases, one of which is abnormalities of chromosome 13. Using the two techniques simultaneously (i.e., cIg-FISH), we have demonstrated that approx 50% of patients with MM have abnormalities of chromosome 13, mostly monosomy, and when present involving the majority of the cells. In this chapter, we present the technical methodology for detecting chromosome abnormalities and how to restrict the analysis to the clonal PCs.

UR - http://www.scopus.com/inward/record.url?scp=22844451257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22844451257&partnerID=8YFLogxK

M3 - Article

VL - 113

SP - 59

EP - 69

JO - Methods in molecular medicine

JF - Methods in molecular medicine

SN - 1543-1894

ER -